RU2010114041A - Применение пептида в качестве терапевтического средства - Google Patents
Применение пептида в качестве терапевтического средства Download PDFInfo
- Publication number
- RU2010114041A RU2010114041A RU2010114041/15A RU2010114041A RU2010114041A RU 2010114041 A RU2010114041 A RU 2010114041A RU 2010114041/15 A RU2010114041/15 A RU 2010114041/15A RU 2010114041 A RU2010114041 A RU 2010114041A RU 2010114041 A RU2010114041 A RU 2010114041A
- Authority
- RU
- Russia
- Prior art keywords
- lys
- tyr
- arg
- diseases
- asp
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 12
- 230000001225 therapeutic effect Effects 0.000 title 1
- 208000019693 Lung disease Diseases 0.000 claims abstract 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 7
- 201000010099 disease Diseases 0.000 claims abstract 6
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract 5
- 208000035473 Communicable disease Diseases 0.000 claims abstract 5
- 206010016654 Fibrosis Diseases 0.000 claims abstract 5
- 201000011510 cancer Diseases 0.000 claims abstract 5
- 230000004761 fibrosis Effects 0.000 claims abstract 5
- 208000015181 infectious disease Diseases 0.000 claims abstract 5
- 208000027866 inflammatory disease Diseases 0.000 claims abstract 5
- 208000030159 metabolic disease Diseases 0.000 claims abstract 5
- 230000004770 neurodegeneration Effects 0.000 claims abstract 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract 5
- 210000004204 blood vessel Anatomy 0.000 claims abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 4
- 208000016097 disease of metabolism Diseases 0.000 claims abstract 3
- 208000017169 kidney disease Diseases 0.000 claims abstract 3
- 208000037803 restenosis Diseases 0.000 claims abstract 3
- 238000011282 treatment Methods 0.000 claims abstract 3
- 208000020084 Bone disease Diseases 0.000 claims abstract 2
- 208000011231 Crohn disease Diseases 0.000 claims abstract 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims abstract 2
- 206010025282 Lymphoedema Diseases 0.000 claims abstract 2
- 208000012902 Nervous system disease Diseases 0.000 claims abstract 2
- 208000007117 Oral Ulcer Diseases 0.000 claims abstract 2
- 208000004756 Respiratory Insufficiency Diseases 0.000 claims abstract 2
- 208000006011 Stroke Diseases 0.000 claims abstract 2
- 208000025865 Ulcer Diseases 0.000 claims abstract 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims abstract 2
- 201000009101 diabetic angiopathy Diseases 0.000 claims abstract 2
- 201000002249 diabetic peripheral angiopathy Diseases 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims abstract 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract 2
- 208000014951 hematologic disease Diseases 0.000 claims abstract 2
- 150000004677 hydrates Chemical class 0.000 claims abstract 2
- 208000028867 ischemia Diseases 0.000 claims abstract 2
- 206010025135 lupus erythematosus Diseases 0.000 claims abstract 2
- 210000001365 lymphatic vessel Anatomy 0.000 claims abstract 2
- 208000002502 lymphedema Diseases 0.000 claims abstract 2
- 208000007106 menorrhagia Diseases 0.000 claims abstract 2
- 210000004400 mucous membrane Anatomy 0.000 claims abstract 2
- 201000011461 pre-eclampsia Diseases 0.000 claims abstract 2
- 230000002265 prevention Effects 0.000 claims abstract 2
- 210000004994 reproductive system Anatomy 0.000 claims abstract 2
- 201000004193 respiratory failure Diseases 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 208000017520 skin disease Diseases 0.000 claims abstract 2
- 208000011580 syndromic disease Diseases 0.000 claims abstract 2
- 230000036269 ulceration Effects 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims 3
- 208000031481 Pathologic Constriction Diseases 0.000 claims 2
- 210000004251 human milk Anatomy 0.000 claims 2
- 235000020256 human milk Nutrition 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 208000037804 stenosis Diseases 0.000 claims 2
- 230000036262 stenosis Effects 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000010392 Bone Fractures Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 239000007853 buffer solution Substances 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 239000002577 cryoprotective agent Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- -1 lyoprotector Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2235—Secretins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
Abstract
1. Сочетание пептидов His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu-Gly-Lys-Arg-Tyr-Lys-Gln-Arg-Val-Lys-Asn-Lys-NH2 и Ac-Met-Trp-Asp-Phe-Asp-Asp-Leu-Asn-Phe-Thr-Gly-Met-Pro-Pro-Ala-Asp-Glu-Asp-Tyr-Ser-Pro-NH2 или их солей, гидратов или деацетилированной формы. ! 2. Сочетание по п.1, где пептиды содержатся в сочетании в количестве от 30% по массе к 70% по массе до 70% по массе к 30% по массе. ! 3. Сочетание по п.1 для применения в медицине. ! 4. Применение пептида по His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu-Gly-Lys-Arg-Tyr-Lys-Gln-Arg-Val-Lys-Asn-Lys-NH2 или сочетания по п.1, или 2, или 3 для получения фармацевтической композиции для лечения и/или профилактики злокачественной опухоли, аутоиммунных заболеваний, фиброзов, воспалительных заболеваний, нейродегенеративных заболеваний, инфекционных заболеваний, заболеваний легких, заболеваний сердца и сосудов и болезней обмена веществ. ! 5. Применение пептида по п.4, где злокачественная опухоль, аутоиммунное заболевание, фиброз, воспалительное заболевание, нейродегенеративное заболевание, инфекционное заболевание, заболевание легких, заболевание сердца и сосудов или болезни обмена веществ выбраны из инфекции HBV, заболеваний нервной системы, заболеваний кровеносных и лимфатических сосудов, болезней кожи, заболеваний репродуктивной системы, заболеваний легких, заболеваний почек, заболеваний костей, бокового амиотрофического склероза, диабетической нейропатии, инсульта, диабетической ангиопатии, сниженной реэндотелиализации при рестенозе, лимфедемы, изъязвлений желудочно-кишечного тракта, язв ротовой полости, ишемии слизистой оболочки при болезни Крона, волчанки, преэклампсии, меноррагии, синдрома дыхательной недостаточности нов
Claims (13)
1. Сочетание пептидов His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu-Gly-Lys-Arg-Tyr-Lys-Gln-Arg-Val-Lys-Asn-Lys-NH2 и Ac-Met-Trp-Asp-Phe-Asp-Asp-Leu-Asn-Phe-Thr-Gly-Met-Pro-Pro-Ala-Asp-Glu-Asp-Tyr-Ser-Pro-NH2 или их солей, гидратов или деацетилированной формы.
2. Сочетание по п.1, где пептиды содержатся в сочетании в количестве от 30% по массе к 70% по массе до 70% по массе к 30% по массе.
3. Сочетание по п.1 для применения в медицине.
4. Применение пептида по His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu-Gly-Lys-Arg-Tyr-Lys-Gln-Arg-Val-Lys-Asn-Lys-NH2 или сочетания по п.1, или 2, или 3 для получения фармацевтической композиции для лечения и/или профилактики злокачественной опухоли, аутоиммунных заболеваний, фиброзов, воспалительных заболеваний, нейродегенеративных заболеваний, инфекционных заболеваний, заболеваний легких, заболеваний сердца и сосудов и болезней обмена веществ.
5. Применение пептида по п.4, где злокачественная опухоль, аутоиммунное заболевание, фиброз, воспалительное заболевание, нейродегенеративное заболевание, инфекционное заболевание, заболевание легких, заболевание сердца и сосудов или болезни обмена веществ выбраны из инфекции HBV, заболеваний нервной системы, заболеваний кровеносных и лимфатических сосудов, болезней кожи, заболеваний репродуктивной системы, заболеваний легких, заболеваний почек, заболеваний костей, бокового амиотрофического склероза, диабетической нейропатии, инсульта, диабетической ангиопатии, сниженной реэндотелиализации при рестенозе, лимфедемы, изъязвлений желудочно-кишечного тракта, язв ротовой полости, ишемии слизистой оболочки при болезни Крона, волчанки, преэклампсии, меноррагии, синдрома дыхательной недостаточности новорожденных, фиброза легких, эмфиземы, нефропатии, гломерулосклероза, тубулоинтерстициального фиброза, остеопороза, нарушенного восстановления перелома костей, ишемической болезни сердца, сердечной недостаточности, стеноза, рестеноза, стеноза внутри стента, атеросклероза, артериосклероза, тромбоза, нарушений заживления ран.
6. Применение пептида His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu-Gly-Lys-Arg-Tyr-Lys-Gln-Arg-Val-Lys-Asn-Lys-NH2 для получения состава для перорального введения новорожденным, детям ясельного возраста и/или детям дошкольного возраста.
7. Применение пептида His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu-Gly-Lys-Arg-Tyr-Lys-Gln-Arg-Val-Lys-Asn-Lys-NH2 для получения лиофилизированного состава или буферного жидкого состава.
8. Применение пептида His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu-Gly-Lys-Arg-Tyr-Lys-Gln-Arg-Val-Lys-Asn-Lys-NH2 или сочетания по п.1, или 2, или 3, для увеличения скоростей реэндотелиализации и ангиогенеза для организации ткани в имплантируемых сосудистых трансплантатах
9. Фармацевтическая композиция, содержащая сочетание по п.1, по меньшей мере, совместно с одним фармацевтически приемлемым носителем, криопротектором, лиопротектором, эксципиентом и/или разбавителем.
10. Фармацевтическая композиция по п.9 в форме лиофилизата или жидкого буферного раствора.
11. Фармацевтическая композиция по п.9 или 10, пригодная для внутривенного введения, перорального введения или для введения посредством ингаляции.
12. Фармацевтическая композиция по п.9 или 10 в форме состава искусственного материнского молока или заменителя материнского молока, пригодная для пероральной доставки новорожденным, детям ясельного возраста и/или детям дошкольного возраста.
13. Фармацевтическая композиция по п.9 или 10, пригодная для лечения и/или профилактики злокачественной опухоли, аутоиммунного заболевания, фиброза, воспалительного заболевания, нейродегенеративного заболевания, инфекционного заболевания, заболевания легких, заболевания сердца и сосудов или болезни обмена веществ.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07017759.7 | 2007-09-11 | ||
| EP07017759 | 2007-09-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2010114041A true RU2010114041A (ru) | 2011-10-20 |
Family
ID=40032721
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010114031/15A RU2010114031A (ru) | 2007-09-11 | 2008-09-09 | Проадреномедуллин индивидуально или в сочетании с большим гастрином i в качестве терапевтического средства |
| RU2010114041/15A RU2010114041A (ru) | 2007-09-11 | 2008-09-09 | Применение пептида в качестве терапевтического средства |
| RU2010113999/15A RU2010113999A (ru) | 2007-09-11 | 2008-09-09 | Применение секретина и необязательно уродилатина в качестве терапевтических средств |
| RU2010114038/15A RU2010114038A (ru) | 2007-09-11 | 2008-09-09 | Применение адреномедуллина в качестве терапевтического средства для лечения избыточного ангиогенеза |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010114031/15A RU2010114031A (ru) | 2007-09-11 | 2008-09-09 | Проадреномедуллин индивидуально или в сочетании с большим гастрином i в качестве терапевтического средства |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010113999/15A RU2010113999A (ru) | 2007-09-11 | 2008-09-09 | Применение секретина и необязательно уродилатина в качестве терапевтических средств |
| RU2010114038/15A RU2010114038A (ru) | 2007-09-11 | 2008-09-09 | Применение адреномедуллина в качестве терапевтического средства для лечения избыточного ангиогенеза |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US20100197586A1 (ru) |
| EP (4) | EP2190533A2 (ru) |
| JP (3) | JP2010539047A (ru) |
| KR (3) | KR20100061479A (ru) |
| AU (4) | AU2008297874A1 (ru) |
| CA (4) | CA2698772A1 (ru) |
| RU (4) | RU2010114031A (ru) |
| WO (7) | WO2009039994A1 (ru) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2691104C2 (ru) * | 2013-08-14 | 2019-06-11 | Лаурантис Фарма Ой | Терапевтическое применение vegf-c и ccbe1 |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008507540A (ja) | 2004-07-21 | 2008-03-13 | チューレン ユニバーシティ ヘルス サイエンス センター | Ｐａｃａｐ化合物を用いる腎臓機能障害及び多発性骨髄腫の治療 |
| CA2738549A1 (en) * | 2008-09-25 | 2010-04-01 | The Administrators Of The Tulane Educational Fund | Use of pituitary adenylate cyclase-activating polypeptide (pacap) and pacap analogs as adjunctive treatments with anticancer agents |
| ES2723098T3 (es) | 2008-11-04 | 2019-08-21 | Janssen Pharmaceutica Nv | Agonistas del péptido CRHR2 y usos de los mismos |
| WO2011003895A1 (en) | 2009-07-07 | 2011-01-13 | N.V. Organon | 2-(1,2-benzisoxazol-3-yl)benzylamine derivatives |
| JP5908406B2 (ja) | 2009-11-02 | 2016-04-26 | ジ アドミニストレーターズ オブ ザ トゥレーン エデュケーショナル ファンド | 下垂体アデニル酸シクラーゼ活性化ポリペプチド（ｐａｃａｐ）の類似体およびその使用方法 |
| WO2013122979A1 (en) * | 2012-02-15 | 2013-08-22 | Chirhoclin, Inc. | Methods for treating pain associated with chronic pancreatitis |
| US11406718B2 (en) | 2012-05-29 | 2022-08-09 | Chirhoclin, Inc. | Methods of detecting pancreobiliary ductal leaks |
| EP3035950A4 (en) * | 2013-08-14 | 2017-05-03 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Glycosylated pacap/vip analogues with enhanced cns penetration for treatment of neurodegenerative diseases |
| CN114805540A (zh) | 2015-09-18 | 2022-07-29 | 国立大学法人宫崎大学 | 长效肾上腺髓质素衍生物 |
| CN108472332B (zh) | 2015-11-13 | 2022-03-18 | 汉阳大学校产学协力团 | 用于通过经鼻施用来治疗中风的组合物 |
| JP6781974B2 (ja) * | 2016-03-31 | 2020-11-11 | 国立大学法人 宮崎大学 | アドレノメデュリン凍結乾燥製剤の製造方法 |
| US11318190B2 (en) * | 2017-05-05 | 2022-05-03 | United States Government As Represented By The Department Of Veterans Affairs | Methods and compositions for treating liver disease |
| US20190287217A1 (en) * | 2018-03-13 | 2019-09-19 | Microsoft Technology Licensing, Llc | Machine learning system for reduced network bandwidth transmission of content |
| CN116034159A (zh) * | 2020-04-02 | 2023-04-28 | 国立大学法人宫崎大学 | 新型肾上腺髓质素类似物及其制备方法和医药用途 |
| US11744878B2 (en) | 2020-08-19 | 2023-09-05 | Chirhoclin, Inc. | Methods for treatment of COVID-19 syndrome |
| JPWO2022054825A1 (ru) * | 2020-09-09 | 2022-03-17 | ||
| JPWO2022054826A1 (ru) * | 2020-09-09 | 2022-03-17 | ||
| WO2025133215A1 (en) * | 2023-12-22 | 2025-06-26 | Pam Theragnostics Gmbh | Use of inactive adrenomedullin precursor for therapeutic purposes |
| WO2025184558A1 (en) | 2024-02-28 | 2025-09-04 | Caradon Therapeutics, Inc. | Modified urocortin 3 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE454513B (sv) * | 1985-03-11 | 1988-05-09 | Kabigen Ab | Humant sekretin samt kompositioner innehallande detta |
| DE69128283T2 (de) | 1991-08-12 | 1998-03-19 | Nestle Sa | Nahrungsmittelzusammensetzung |
| DE4216133A1 (de) * | 1992-05-15 | 1993-11-18 | Bissendorf Peptide Gmbh | Anwendung von Urodilatin bei Lungen- und Bronchialerkrankungen |
| JPH06228002A (ja) * | 1993-01-29 | 1994-08-16 | Takeda Chem Ind Ltd | Ｐａｃａｐを含有するセクレトグラニンιι産生促進剤 |
| ES2163504T5 (es) | 1994-05-06 | 2008-05-16 | Pfizer Inc. | Formas de dosificacion de liberacion controlada de azitromicina. |
| WO1996009318A1 (en) * | 1994-09-22 | 1996-03-28 | The Administrators Of The Tulane Educational Fund | Method and pharmaceutical composition for prevention and treatment of brain damage |
| DE69602756T2 (de) * | 1995-08-18 | 2000-02-10 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Rockville | Funktionelle rolle von adrenomedullin(am) und dem gen-verwandten produkt(pamp) in der menschlichen pathologie und physiologie |
| CZ262698A3 (cs) | 1996-02-19 | 1999-03-17 | Nycomed Imaging A/S | Kontrastní prostředek pro zobrazování ultrazvukem a způsob jeho výroby |
| TW360501B (en) | 1996-06-27 | 1999-06-11 | Nestle Sa | Dietetically balanced milk product |
| ATE193636T1 (de) | 1996-09-24 | 2000-06-15 | Nestle Sa | Milchaustauschprodukt und verfahren zu dessen herstellung |
| AU1918299A (en) * | 1998-02-23 | 1999-09-06 | Warner-Lambert Company | Substituted quinoxaline derivatives as interleukin-8 receptor antagonists |
| AU771034B2 (en) | 1998-11-24 | 2004-03-11 | Societe Des Produits Nestle S.A. | Method for preparing a protein composition and an infant formula containing same |
| GB0016441D0 (en) * | 2000-07-04 | 2000-08-23 | Pharmagene Lab Limited | Therapeutic method |
| US20020082409A1 (en) * | 2000-10-26 | 2002-06-27 | Hsu Sheau Yu | Stresscopins and their uses |
| IL154553A0 (en) * | 2001-03-15 | 2003-09-17 | Res Dev Foundation | Urocortin-iii and uses thereof |
| EP1389126B1 (en) * | 2001-04-18 | 2016-12-21 | The Regents of The University of California | Retrocyclins: antiviral and antimicrobial peptides |
| EP1314357B1 (en) | 2001-11-23 | 2007-05-23 | Société des Produits Nestlé S.A. | Process for the preparation of milk powders and concentrated milk products |
| US6936585B2 (en) * | 2002-01-16 | 2005-08-30 | The Procter & Gamble Company | Corticotropin releasing factor 2 receptor agonists |
| US20040229810A1 (en) * | 2002-10-22 | 2004-11-18 | Antonio Cruz | Gastrin compositions and formulations, and methods of use and preparation |
| US7462593B2 (en) * | 2002-11-07 | 2008-12-09 | Us Gov Health & Human Serv | Compositions and methods for promoting angiogenesis |
| US20040152634A1 (en) * | 2002-12-24 | 2004-08-05 | Navarro Javier V. | Chemokine antagonists and uses thereof |
| US8703693B2 (en) * | 2004-03-31 | 2014-04-22 | The Feinstein Institute For Medical Research | Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment |
| CA2477867A1 (en) * | 2004-09-17 | 2006-03-17 | Oncorex, Inc. | Peptides, dna's, rna's, and compounds for inhibiting or inducing adrenomedullin activity, and use of the same |
| KR20070112155A (ko) * | 2005-02-08 | 2007-11-22 | 리서치 디벨럽먼트 파운데이션 | 가용성 Ｇ-단백질 연결 수용체(ｓＧＰＣＲ)와 관련된조성물 및 방법 |
| JP4830093B2 (ja) * | 2005-04-08 | 2011-12-07 | 国立大学法人 宮崎大学 | 非細菌性の炎症性疾患の予防又は治療剤 |
| JP2006306770A (ja) * | 2005-04-27 | 2006-11-09 | Nidek Co Ltd | 眼疾患治療剤 |
| EP1900374B1 (en) * | 2005-06-16 | 2014-03-12 | Takayuki Shindo | Angiogenetic agent containing adrenomedulin as the active ingredient |
| US20090035287A1 (en) * | 2005-09-26 | 2009-02-05 | Zurit Levine | Atrial natriuretic peptide (anp) splice variants and methods of using same |
| US20100144613A1 (en) * | 2005-10-07 | 2010-06-10 | Antonio Cruz | Combined use of DPP-IV Inhibitors and Gastrin Compounds |
| WO2007044998A1 (en) * | 2005-10-12 | 2007-04-19 | The Regents Of The University Of California | Retrocyclins: antiviral and antimicrobial peptides |
| WO2007090087A2 (en) * | 2006-01-27 | 2007-08-09 | Research Development Foundation | Use of corticotropin releasing factor receptor-2 inhibitors for treating insulin-related diseases |
| WO2007095737A1 (en) * | 2006-02-21 | 2007-08-30 | Waratah Pharmaceuticals Inc. | Combination therapy for the treatment of diabetes comprising an exendin agonist and a gastrin compound |
| US7982018B2 (en) * | 2006-10-16 | 2011-07-19 | Conjuchem, Llc | Modified corticotropin releasing factor peptides and uses thereof |
-
2008
- 2008-09-09 AU AU2008297874A patent/AU2008297874A1/en not_active Abandoned
- 2008-09-09 EP EP08802392A patent/EP2190533A2/en not_active Withdrawn
- 2008-09-09 US US12/677,104 patent/US20100197586A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/007544 patent/WO2009039994A1/en not_active Ceased
- 2008-09-09 AU AU2008303893A patent/AU2008303893A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/007736 patent/WO2009040027A1/en not_active Ceased
- 2008-09-09 RU RU2010114031/15A patent/RU2010114031A/ru not_active Application Discontinuation
- 2008-09-09 RU RU2010114041/15A patent/RU2010114041A/ru not_active Application Discontinuation
- 2008-09-09 KR KR1020107005598A patent/KR20100061479A/ko not_active Ceased
- 2008-09-09 CA CA2698772A patent/CA2698772A1/en not_active Abandoned
- 2008-09-09 CA CA2699153A patent/CA2699153A1/en not_active Abandoned
- 2008-09-09 US US12/677,518 patent/US20100184676A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/007542 patent/WO2009033700A1/en not_active Ceased
- 2008-09-09 EP EP08802267A patent/EP2197467A2/en not_active Ceased
- 2008-09-09 WO PCT/EP2008/007881 patent/WO2009033767A2/en not_active Ceased
- 2008-09-09 KR KR1020107005596A patent/KR20100061478A/ko not_active Withdrawn
- 2008-09-09 CA CA2699167A patent/CA2699167A1/en not_active Abandoned
- 2008-09-09 JP JP2010523420A patent/JP2010539047A/ja active Pending
- 2008-09-09 EP EP08785862A patent/EP2185179A1/en not_active Withdrawn
- 2008-09-09 AU AU2008303956A patent/AU2008303956A1/en not_active Abandoned
- 2008-09-09 US US12/677,570 patent/US20100197588A1/en not_active Abandoned
- 2008-09-09 AU AU2008297542A patent/AU2008297542A1/en not_active Abandoned
- 2008-09-09 RU RU2010113999/15A patent/RU2010113999A/ru not_active Application Discontinuation
- 2008-09-09 CA CA2698770A patent/CA2698770A1/en not_active Abandoned
- 2008-09-09 EP EP08802099A patent/EP2187939A1/en not_active Withdrawn
- 2008-09-09 JP JP2010523376A patent/JP5385277B2/ja not_active Expired - Fee Related
- 2008-09-09 RU RU2010114038/15A patent/RU2010114038A/ru not_active Application Discontinuation
- 2008-09-09 WO PCT/EP2008/007709 patent/WO2009043481A2/en not_active Ceased
- 2008-09-09 JP JP2010523374A patent/JP2010539001A/ja active Pending
- 2008-09-09 US US12/677,106 patent/US20100184674A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/007738 patent/WO2009040029A2/en not_active Ceased
- 2008-09-09 KR KR1020107005645A patent/KR20100059862A/ko not_active Withdrawn
- 2008-09-09 WO PCT/EP2008/007812 patent/WO2009046822A2/en not_active Ceased
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2691104C2 (ru) * | 2013-08-14 | 2019-06-11 | Лаурантис Фарма Ой | Терапевтическое применение vegf-c и ccbe1 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010114041A (ru) | Применение пептида в качестве терапевтического средства | |
| RU2010113986A (ru) | Применение пептида в качестве терапевтического средства | |
| RU2010114042A (ru) | Применение пептида в качестве терапевтического средства | |
| RU2010113974A (ru) | Применение противовоспалительного пептида-1 в качестве терапевтического средства | |
| RU2010114024A (ru) | Применение гонадорелина в качестве терапевтического средства | |
| RU2010114033A (ru) | Применение ингибитора nf-каппа в sn50 и необязательно ангиотензина iii в качестве терапевтических средств при лечении, например, инфекции hbv | |
| RU2010114014A (ru) | Применение глюкагона (1-29) отдельно или в сочетании с нейропептидом w30 в качестве терапевтического средства | |
| RU2010114000A (ru) | Применение нейропептида sf индивидуально или в сочетании с glp-2 в качестве терапевтического средства | |
| RU2010113989A (ru) | Применение пептида в качестве терапевтического средства | |
| RU2010113979A (ru) | Применение bubuc и необязательно eaa-marti (26-35) в качестве терапевтического средства для лечения инфекций hcmv | |
| RU2010114045A (ru) | Применение пептида sfllr-oh и мурамилдипептида в качестве терапевтических средств | |
| RU2010113998A (ru) | Применение пептида rfmwmr в качестве терапевтического средства | |
| RU2010114030A (ru) | Применение пептида в качестве терапевтического средства | |
| RU2010114051A (ru) | Применение grf-1(1-29) и кортиколиберина в качестве терапевтических средств | |
| RU2010114049A (ru) | Cgrp в качестве терапевтического средства | |
| WO2009039977A3 (en) | Use of alpha-casein (90-96) as a therapeutic agent in eg the treatment of hbv infection | |
| RU2010114050A (ru) | Применение пептида рецептора il-1 индивидуально или в комбинации с октадециловым эфиром d-ala-gln в качестве терапевтического средства | |
| RU2010114039A (ru) | Применение октреотида в качестве терапевтического средства | |
| RU2010114005A (ru) | Применение сочетания пептидов тимозина бета4 и индуцирующего дельта-сон пептида в качестве терапевтического средства | |
| RU2010114035A (ru) | Применение rfrp индивидуально или в комбинации с нейрокинином в в качестве терапевтического средства | |
| RU2010114037A (ru) | Применение белка полосы 3 и расар-27 в качестве терапевтического средства | |
| RU2010114060A (ru) | Применение пептида в качестве терапевтического средства |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20110912 |